Copyright
©The Author(s) 2019.
World J Gastroenterol. Apr 7, 2019; 25(13): 1592-1602
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1592
Published online Apr 7, 2019. doi: 10.3748/wjg.v25.i13.1592
Table 2 Clinical characteristics of the patients with upper gastrointestinal bleeding and efficacy of hemostatic powders in the treatment of upper gastrointestinal bleeding n (%)
HS and EC (n = 137) | Hemospray (n = 102) | Endoclot (n = 25) | P value | |
Sex (M) | 86 (62.8) | 68 (66.7) | 11 (44) | 0.04 |
Age, yr | ||||
mean ± SD | 66.4 ± 14.2 | 66.4 ± 14.0 | 67.9 ± 16.5 | NS |
range | (11-93) | 29-93 | 11-89 | |
Rockall risk score | NS | |||
median ± SD | 7.1 ±1.7 | 7.1 ± 1.7 | 7.1 ± 1.8 | |
range | 2-10 | 2 -10 | 2 - 10 | |
Comorbidities | ||||
Coagulopathy | 45 (32.8) | 34 (33) | 5 (2) | |
Renal insufficiency | 68 (49.6) | 59 (49) | 12 (48) | |
Hemodialysis | 32 (23.4) | 24 (23) | 12 (48) | |
Liver cirrhosis | 38 (27.7) | 30 (29.4) | 5 (20) | |
Therapeutic anticoagulation | 35 (25.5) | 28 (27.5) | 6 (24) | |
Dual antiplatet therapy | 7 (5.1) | 5 (5) | 2 (8) | |
Vitamin K antagonists | 14 (10.2) | 11 (11) | 3 (12) | |
DOAC | 8 (5.8) | 7 (7) | 1 (4) | |
Antiaggregation therapy | 29 (21.2) | 21 (20.6) | 7 (28) | |
Application as | NS | |||
Primary Therapy | 72 (52.6) | 59 (58) | 10 (40) | |
Salvage Therapy | 65 (47.4) | 43 (42) | 15 (60) | |
Multiple Applications of | NS | |||
HS | 37 (27) | 24 (23) | 3 (0.12) | |
Definite hemostatic therapies after HP failure | NS | |||
Coiling | 13 (9.5) | 11 (11) | 1 (4) | |
Surgery | 8 (5.8) | 7 (6.9) | 0 | |
Short term success (total) | 113/137 (82.5) | 68/102 (66.6) | 21/25 (84) | NS |
Primary therapy | 60/72 (83.3) | 50/59 (84.7) | 8/10 (80) | |
Salvage therapy | 53/65 (81.5) | 36/43 (83.7) | 13/15 (86.6) | |
Long term success | 71/108 (65.7) | 53/78 (67.9) | 15/22 (68.2) | NS |
Primary therapy | 39/57 (68.4) | 32/45 (71) | 6/10 (60) | |
Salvage therapy | 32/51 (62.7) | 21/33(63.6) | 9/12 (75) | |
Re-bleeding rate | 34/137 (24.8) | 24/102 (23.5) | 4/25 (16) | NS |
Primary therapy | 15/72 (20.8) | 11/59 (18.6) | 2/10 (20) | |
Salvage therapy | 19/65 (29.2) | 13/43 (30.2) | 2/15 (13) |
- Citation: Vitali F, Naegel A, Atreya R, Zopf S, Neufert C, Siebler J, Neurath MF, Rath T. Comparison of Hemospray® and Endoclot™ for the treatment of gastrointestinal bleeding. World J Gastroenterol 2019; 25(13): 1592-1602
- URL: https://www.wjgnet.com/1007-9327/full/v25/i13/1592.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i13.1592